Want to join the conversation?
$BIIB expects R&D expense for 2016 to be approx. 19% to 20% of sales, including about $100MM earmarked for business development activity. The Company plans to continue to invest in a number of R&D programs across late-stage pipeline during 2016, including aducanumab for Alzheimer's disease and nusinersen for spinal muscular atrophy.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.